Dr. Kalfus is a Medical Director at RedHill Biopharma, which is currently conducting a Phase III FDA trial of a specific combination of antibiotics in Crohn’s disease patients. In his presentation, Dr. Kalfus gives the reason behind triple therapy for MAP and how the three antibiotics were selected. He also talks about how the currently available Crohn’s therapies have some anti-MAP activity. MAP diagnostics, the Selby study and the ongoing RedHill study are also discussed.
2017 MAP Conference | Unacknowledged Growth Inhibition of MAP by Immunomodulators
Dr. Greenstein is a researcher in the Laboratory of Molecular Surgical Research at the VA Medical Center in Bronx, NY. He presents his research explaining why he believes that the primary action of current Crohn’s disease therapies is really Anti-MAP, and hypothesizes that Crohn’s disease may be the tip of the MAP iceberg. The antimycobacterial effect of Vitamin D is also discussed.
2017 MAP Conference | Evidence that Crohn’s Disease is a Disease of Innate Immune Deficiency
Dr. Chamberlin is a gastroenterologist at the San Antonio Military Medical Center in Texas. In his second presentation, he outlines why he believes that Crohn’s disease is both a disease of immune deficiency and also an infectious disease. The immune system is reviewed, differences in the innate and adaptive immune system are discussed, and genetic mutations which allow MAP to take advantage of certain immune pathways are detailed. Compounds which may stimulate autophagy like turmeric and Vitamin D are discussed. A Q&A session follows the presentation.
2017 MAP Conference | Implication of MAP Infection in Cattle with Implications for Infection in Humans
Appearing by WebEx at the conference, Dr. Davis is a researcher and professor in the Department of Veterinary Microbiology and Pathology at Washington State University. Here, he summarizes the findings from his 27 year MAP study and provides an update on his progress in developing a cattle vaccine for MAP that may have insights into human MAP as well.
2017 MAP Conference | MAP, Type 1 Diabetes and Multiple Sclerosis. What is the Connection?
Appearing at the conference via Webex, Dr. Sechi is a Professor of Microbiology at the University of Sassari, Sardinia, Italy. Sardinia is an island with some of the highest rates of autoimmune diseases in the world. MAP is commonly found in their ruminant population as well. Dr. Sechi’s research shows significantly higher rates of MAP in patients with autoimmune diseases like multiple sclerosis and Type 1 Diabetes. He presents some of that research here, and discusses a mechanism for MAP infection in these diseases which may differ than that in Crohn’s disease. Questions from the audience follow the presentation.